A global, innovation-driven, biopharmaceutical company
- AstraZeneca’s sales and profits have declined over the last years due to a number of key products going off patents.
- To achieve future growth, it is important that AstraZeneca brings new and innovative treatments to the market.
- Encouraging pipeline progress has been made in recent years, although readouts in 2017 were mixed. The coming years will be important in terms of late-stage pipeline readouts and commercialization of approved products.
Visit the company website